Susan Ellard

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

Daniel Khalaf, Matti Annala, Sinja Taavitsainen et al. · The Lancet Oncology · 2019 · 352 citations

Medicine, Oncology, Pharmacotherapy +17

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

Krista Noonan, Scott North, Rhonda L. Bitting et al. · Annals of Oncology · 2013 · 341 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

Susan Ellard, Mark Clemons, Karen A. Gelmon et al. · Journal of Clinical Oncology · 2009 · 261 citations

Medicine, Oncology, Pharmacology +16

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Stéphanie Lheureux, Mihaela Cristea, Jeffrey P. Bruce et al. · The Lancet · 2021 · 211 citations · Full text

Medicine, Oncology, Pharmacology +10